A Study to Evaluate Efficacy and Safety of LCI699 in Participants With Essential Hypertension

NCT00758524 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

628

Enrollment

INDUSTRY

Sponsor class

Conditions

Essential Hypertension

Interventions

DRUG: LCI699
DRUG: Eplerenone
DRUG: LCI699-matching Placebo
DRUG: Eplerenone-matching Placebo

Sponsor

Novartis Pharmaceuticals